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Abstract
Background: The non-canonical Wnt/Planar cell polarity (PCP) signaling pathway is a major player in cell migration
during embryonal development and has recently been implicated in tumorigenesis.
Methods: Transfections with cDNA plasmids or siRNA were used to increase and suppress Prickle1 and Vangl2
expression in neuroblastoma cells and in non-tumorigenic cells. Cell viability was measured by trypan blue
exclusion and protein expression was determined with western blotting. Transcriptional activity was studied with
luciferase reporter assay and mRNA expression with real-time RT-PCR. Immunofluorescence stainings were used to
study the effects of Vangl2 overexpression in non-tumorigenic embryonic cells. Statistical significance was tested
with t-test or one-way ANOVA.
Results: Here we show that high expression of the PCP core genes Prickle1 and Vangl2 is associated with low-risk
neuroblastoma, suppression of neuroblastoma cell growth and decreased Wnt/β-catenin signaling. Inhibition of
Rho-associated kinases (ROCKs) that are important in mediating non-canonical Wnt signaling resulted in increased
expression of Prickle1 and inhibition of β-catenin activity in neuroblastoma cells. In contrast, overexpression of
Vangl2 in MYC immortalized neural stem cells induced accumulation of active β-catenin and decreased the neural
differentiation marker Tuj1. Similarly, genetically modified mice with forced overexpression of Vangl2 in nestin-
positive cells showed decreased Tuj1 differentiation marker during embryonal development.
Conclusions: Our experimental data demonstrate that high expression of Prickle1 and Vangl2 reduce the growth of
neuroblastoma cells and indicate different roles of PCP proteins in tumorigenic cells compared to normal cells. These
results suggest that the activity of the non-canonical Wnt/PCP signaling pathway is important for neuroblastoma
development and that manipulation of the Wnt/PCP pathway provides a possible therapy for neuroblastoma.
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Background
Neuroblastoma, an embryonic tumor of the peripheral
sympathetic nervous system is the most common and
deadly tumor of childhood [1]. These tumors are clinically
and biologically heterogeneous ranging from highly prolif-
erative tumors that undergo spontaneous apoptosis with
little or no treatment to highly malignant metastasizing
tumors that are difficult to cure with current treatment
strategies [1, 2]. Primary neuroblastoma occurs in the ad-
renal medulla and the paraspinal sympathetic ganglia and
likely derives from cells within the neural crest [3]. The
neural crest is a transient population of multipotent mi-
gratory cells emerging from the dorsal neural tube and
gives rise to a wide variety of different cells including
those of the sympathetic lineage [4]. During formation of
the neural crest a combined action of fibroblast growth
factor, bone morphogenetic protein and Wingless (Wnt)
signaling is required to specify the location of neural crest
cells at the neural plate border [5]. Neural crest cells
* Correspondence: cecilia.dyberg@ki.se
†Equal contributors
1Childhood Cancer Research Unit, Department of Women’s and Children’s
Health, Karolinska Institutet, Astrid Lindgren Children’s Hospital Q6:05, SE-171
76 Stockholm, Sweden
Full list of author information is available at the end of the article
© 2016 Dyberg et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dyberg et al. BMC Cancer  (2016) 16:259 
DOI 10.1186/s12885-016-2293-2
migrate from the neural plate in a process equivalent to
epithelial-mesenchymal transition (EMT) in which the
cells locomotion, orientation and polarization are con-
trolled mainly by the non-canonical Wnt/Planar cell po-
larity (PCP) signaling cascade [6]. Inappropriate neural
crest cell migration and differentiation may lead to ectopic
tissue formation and is associated with a number of dis-
eases including neuroblastoma [7].
The most distinct marker for poor survival in neuro-
blastoma is MYCN gene amplification which is found in
approximately 40 % of high-risk neuroblastomas [8].
However, high-risk neuroblastomas without MYCN gene
amplification frequently display increased levels of active
β-catenin and activation of canonical Wnt/β-catenin sig-
naling [9]. The non-canonical Wnt/PCP core proteins
Prickle1 and Van Gogh-like 2 (Vangl2) have recently
been shown to attenuate with canonical Wnt/β-catenin
signaling partly by destabilization of β-catenin [10, 11].
This has led to the suggestion that these proteins may
behave as tumor suppressors in certain cancers [10].
In this study we have investigated the effects of
manipulating the expression levels of PCP proteins in
neuroblastoma cells. We analyzed neuroblastoma ex-
pression cohorts and show that high expression of the
PCP proteins Prickle1 and Vangl2 correlates with low-
risk disease and patient survival. Genetic knock-down of
the core PCP genes Prickle1 or Vangl2 resulted in in-
creased growth of neuroblastoma cells and increased ac-
tive β-catenin levels, while overexpression had the
opposite effect. Also pharmacological inhibition of Rho-
associated coiled-coil kinase (ROCK), an important
downstream effector of non-canonical Wnt signaling re-
sulted in increased expression of Prickle1 and reduced
levels of active β-catenin. In contrast, in non-tumorigenic
neural stem cells Vangl2 knockdown decreased cell
growth and increased differentiation while overexpres-
sion showed impaired differentiation. These results
were also confirmed in transgenic mouse embryos




Neuroblastoma cells were cultured in RPMI 1640 (SK-N-
AS, SK-N-BE (2), SK-N-DZ, SK-N-FI, IMR-32, Kelly, SH-
EP1 and SK-N-SH) or Dulbecco’s modified Eagle’s medium
(DMEM)/F12 (SH-SY5Y), supplemented with 10 % fetal
bovine serum (FBS), 2 mM L-glutamine, and antibiotics
(streptomycin and penicillin) from GIBCO (Life Technolo-
gies, Thermo Fisher Scientific Inc., Waltham, MA USA)
[12]. The MYC immortalized neural stem cells line C17.2
[13, 14] was cultivated in DMEM supplemented with 10 %
FBS, 5 % horse serum, 2 mM L-glutamine and antibiotics
(GIBCO). Experiments were performed in Opti-MEM
(GIBCO) supplemented with glutamine and antibiotics,
except for transfection experiments, which were per-
formed without antibiotics. The identities of the neuro-
blastoma cell lines were verified by short tandem repeat
genetic profiling using the AmpFlSTR Identifiler PCR
Amplification Kit (Applied Biosystems, Life Technologies,
Thermo Fisher Scientific Inc., Stockholm, Sweden) in
October 2015 and all cell lines were used in passages
below 25.
Transfections
Cells were transfected using Lipofectamine 2000 (Invitro-
gen, Life Technologies) according to the manufacturer’s in-
structions and incubated for 48 h before analysis.
Expression plasmids for hPrickle1, hVangl2 and cDNA
control were a kind gift (provided respectively by Dr. A.
Bassuk at the University of Iowa and Dr. L. Braiterman at
the Johns Hopkins University School of Medicine). Silen-
cing RNA (siRNA) hairpins (Stealth siRNA duplex oligori-
bonucleotides) complementary to human Prickle1 and
Vangl2 mRNAs were designed by Invitrogen. Alternative
siRNA sequences (Santa Cruz Biotechnology, Dallas,
Texas USA), complementary to human Prickle1 and
Vangl2 mRNAs were used in confirmative transfection ex-
periments. The siRNAs used were a pooled cocktail with
three different siRNA sequences. β-catenin knockdown
was achieved using the SignalSilence β-catenin kit (Cell
Signaling Technology, Beverly, MA). Non-silencing siRNA
was used as control (Cell Signaling Technology). The final
concentration of RNA when added to the cells was 33 nM.
Viability assay
The viability effects of PCP gene expression (siRNA/
overexpression by cDNA) on neuroblastoma cells were
determined using trypan blue exclusion and manually
counting in microscope chambers. Briefly, cells were
seeded in 25 cm2 culture flasks, allowed to attach over-
night, and transfected with cDNA or siRNA constructs
of the PCP gene of interest for 48 h. Cells were then
harvested and counted. All viability experiments were
repeated at least three times.
Drug treatments
To inhibit ROCK cells were drug treated with HA1077
(Fasudil, LC laboratories, Boston USA) (dissolved in
PBS, tested in 25 μM and 50 μM, 72 h) or Y27632 (LC
laboratories) (dissolved in dimethyl sulfoxide, tested in
80 μM, 72 h) and then further analyzed.
Western blotting
Harvested cell pellets were lysed for 15 min with ice-
cold lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM
sodium chloride, 0.1 % SDS, 1 mM EDTA, 1× Roche
protease inhibitor cocktail). For Western blot analyses,
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samples containing equal amounts of protein were sepa-
rated by gel electrophoresis and electroblotted onto
Hybond-P membranes (Amersham Pharmacia, Cleveland,
OH USA). Blots were blocked with 5 % skim milk,
followed by incubation with antibodies specific for anti-
Vangl2 (1:1000, R&D Systems, Minneapolis, MN USA),
anti-Prickle1 (1:1000; Santa Cruz Biotechnology), anti-full
length β-catenin (1:1000, Cell Signaling Technology), anti-
active β-catenin (1:1000, clone 8E7, Millipore, Solna,
Sweden), anti-Axin2 (1:1000, Cell Signaling Technology),
anti-β-actin (1:5000, Cell Signaling Technology) and anti-
GADPH (1:10000, Millipore). Blots were further incubated
with goat anti-rabbit or anti-mouse secondary antibody
conjugated to horseradish peroxidase (Amersham) ac-
cordingly to manufactures instruction and developed on
Kodak hyperfilm. Quantification of blots were done with
densitometry measurements in ImageJ [15].
Real-time RT-PCR analyses
The mRNA expression levels of Prickle1, Vangl2 and en-
dogenous housekeeping genes were quantified using
TaqMan® technology on an ABI PRISM 7500 sequence de-
tection systems (Applied Biosystems) or performed with
Power SYBR Green master mix (Life technologies) on a
7300 Real-Time PCR system (Life technologies). The
TaqMan® sequence-specific primers included Vangl2
(Hs00393412_m1), Prickle1 (Hs01055551_m1), and 18S
ribosomal RNA (Hs99999901_s1) (Applied Biosystems).
Primer sequences for SYBR Green were as followed:
Vangl2: F: TCTACAACGTTGGCCATCTCAGC and R:
ACACCTTGAAGCCAGACACTTTC. Prickle1: F: TG
CTCAGCGGAAGAAAGAAGCAC and R: AGCATGC
ATGACTGCTCTGGAC. GAPDH: F: GAAATCCC
ATCACCATCTTCCAGG and R: GAGCCCCAGCC
TTCTCCATG.
To create a standard curve for relative quantification
we used cDNA synthesized from 1 μg RNA. Total RNA
was prepared from cultured cells using the RNeasy Mini
Kit (Qiagen AB, Sollentuna, Sweden) or TRIzol reagent
(Life technologies) according to manufacturers protocol.
The cDNA synthesis was performed using High capacity
RNA-to-cDNA kit (Applied Biosystems) or High cap-
acity cDNA reverse transcription kit (Life technologies).
All real-time RT–PCR experiments included a no tem-
plate control and were performed in triplicate.
Luciferase reporter assay
Cells were seeded in 24-well plates, left to attach and
transfected with a T-cell factor/lymphoid enhancing fac-
tor (TCF/LEF) reporter plasmid (Super 8× TOPFlash;
400 ng), a Renilla-Luc plasmid (40 ng) and siRNA con-
structs for Prickle1 or Vangl2 using Lipofectamine 2000
(Invitrogen). Alternatively cells were transfected with the
TCF/LEF reporter plasmid and the Renilla-Luc plasmid
and 24 h later, drug treated with the ROCK inhibitor
HA1077. A Dual Luciferase Assay Kit (Promega, Fitchburg,
Wisconsin USA) and a luminometer (Perkin Elmer,
Waltham Massachusetts USA) were used to measure lumi-
nescence. The values were normalized to the Renilla re-
porter before calculating relative levels.
Generation of the Vangl2-HA and nestin-Vangl2
transgenic embryos
A 1566-bp fragment spanning the open reading frame of
Vangl2 and flanked by XhoI and HindIII sites was gener-
ated by PCR from a cDNA clone containing the Vangl2
coding sequence [I.M.A.G.E. Consortium (LLNL) cDNA
CloneID 6509008 [16]] purchased from RZPD
(www.rzpd.de; RZPD CloneID IMAGp998J1714075Q3).
It was then inserted into the XhoI and/or HindIII site of
the pcDNA3-HA expression vector or the NotI site of
the human nestin (hnestin) 1852 vector [17, 18]. The ex-
pression cassette, hnestin 1852/tk promoter Vangl2 ORF
was used for pronuclear injection of fertilized mouse oo-
cytes. The transgenic mouse embryos were generated at
the Karolinska Center for Transgene Technologies using
standard techniques. Shortly, oocytes from female
B6D2F1 (F1 strain of C57B1/6 × DBA2) mated with male
B6D2F1, were retrieved from the oviducts and the DNA
construct was injected into the male pronucleus. Fertil-
ized zygots were then reimplanted into a pseudopreg-
nant foster female (NMRI strain). Pregnant females with
embryos of E8.5 or E9.5 were sacrificed by spinal dis-
location, and the embryos were rapidly dissected out.
Yolk sac DNA was used to genotype transgenic mouse
embryos. To identify transgenics, PCR was performed
with a sense primer complementary to human nestin in-
tron 2 combined with an antisense primer complemen-
tary to the Vangl2 ORF. Mice were kept at maximum of
six per cage and were given water and food ad libitium.
The animal experiment was recorded according to the
guidelines given in the ARRIVE protocol [19]. All animal
experiments were approved by the Northern Stockholm
ethics committee for animal research (N163/03 and
N142/06), appointed and under the control of the
Swedish Board of Agriculture and the Swedish Court.
The animal experiments presented herein were in ac-
cordance with national regulations (SFS 1988:534, SFS
1988:539 and SFS 1988:541) and European Communi-
ties Council guidelines (directive 86/609/EEC).
Immunohistochemistry
Embryos were fixed overnight in 4 % paraformaldehyde
in PBS (pH 7.4) and cryoprotected overnight in 30 % su-
crose in phosphate-buffered saline (PBS). The embryos
were then embedded in mounting medium (Tissue-Tek)
and rapidly frozen. 12-μm sections were collected in a
cryostat (Leica CM3050S; Leica Microsystems Nussloch
Dyberg et al. BMC Cancer  (2016) 16:259 Page 3 of 14
GmbH, Germany) and blocked in 5 % goat serum
(Jackson Immunoresearch Laboratories, West Grove,
PA), and 0.03 % Triton X-100 (Amersham) in PBS for
45 min followed by overnight incubation with primary
antibodies in PBS with 5 % goat serum and 0.03 %
Triton X-100. The following antibodies and dilutions
were used: mouse anti-beta- III/Tuj1 (1:500, Covance,
Princeton, NJ, United States of America), rabbit anti-HA
(1:200, Sigma), rabbit anti-phospho-Histone-3 (1:2000,
Merck Chemicals, Merck Chemicals and Life Science AB,
Stockholm, Sweden). Followed by incubation 1 h room
temperature with the appropriate Alexa fluor-conjugated
secondary antibodies (Molecular Probes, Invitrogen) at a
1:400 dilution in PBS with 5 % goat serum and 0.03 %
Triton X-100. Finally sections were rinsed and mounted
in Vectashield Hard Set mounting medium.
C17.2 cells were fixed with 4 % paraformaldehyde,
permeabilized and blocked in 7 % non-fat dry milk and
0.1 % Triton X-100 in PBS. Primary antibodies were in-
cubated at 4 °C overnight. Primary antibodies used were
anti-β-catenin (1:200, Merck Chemicals) and mouse
anti-beta- III/Tuj1 (1:500, Covance, Princeton, NJ,
United States of America). Followed by incubation 1 h
room temperature with the appropriate Alexa fluor-
conjugated secondary antibodies diluted in PBS and
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Fig. 1 Active β-catenin, Prickle1 and Vangl2 are differently expressed in neuroblastoma cell lines. a Protein expression of active, de-phoshorylated
β-catenin, the canonical Wnt/β-catenin target gene Axin2 and b. total β-catenin in neuroblastoma cell lines. SK-N-BE (2), SK-N-DZ, IMR-32 and
Kelly are MYCN amplified neuroblastoma cells with high MycN expression. SH-SY5Y, SK-N-SH and SK-N-FI are non-MYCN amplified neuroblastoma
cells expressing relatively low levels of MycN whereas, SK-N-AS and SHEP-1 do not show any MycN expression [33] c. Quantified protein expression
(adjusted to β-actin) of Prickle1 and Vangl2 in neuroblastoma cell lines. Proteins were determined with western blotting. d mRNA expression in
neuroblastoma cell lines SK-N-BE (2), SK-N-DZ, SK-N-AS, SH-EP1 and SH-SY5Y, assessed by quantitative real-time PCR, the data displayed is the mean ±
S.D. of three determinations






Fig. 2 (See legend on next page.)
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Fluorescent images were captured with a Nikon axiocam
fluorescence microscope, 20× objective. Contrast images
were acquired in a Nikon Eclipse TS100 microscope,
20× objective.
Statistical analysis
Differences between two groups were determined using
two-sided t-test and for three or more groups one-way
ANOVA with Bonferroni post-test was used. Kaplan-
Meier survival estimates and gene correlation graphs
were extracted from the R2 database (R2: microarray
analysis and visualization platform (http://r2.amc.nl)).
Results
Differential expression and interaction of PCP proteins in
neuroblastoma
The expression of active β-catenin was evaluated to
screen for canonical Wnt signaling activity in neuro-
blastoma cell lines. All nine investigated neuroblastoma
cell lines displayed active β-catenin, i.e. the dephosphor-
ylated nuclear form, as well as the canonical Wnt target
gene Axin2, regardless of MYCN gene amplification sta-
tus [12] (Fig. 1a). However, the highest levels of active β-
catenin were detected in SK-N-AS and SH-SY5Y cells
that are either MYCN deficient or express low levels of
MYCN, respectively. TheMYCN amplified neuroblastoma
cell lines IMR-32 and SK-N-BE (2) showed the lowest
levels of active β-catenin (Fig. 1a). All neuroblastoma cell
lines expressed abundant levels of total β-catenin (Fig. 1b)
Next, we investigated the level of the PCP core proteins
Prickle1 and Vangl2 in neuroblastoma cells. Protein ex-
pression of Prickle1 and Vangl2 were detected in all tested
neuroblastoma cell lines (Fig. 1c). We normalized the na-
tive expression levels against β-actin and compared the
expression levels of the PCP proteins Prickle1 and Vangl2
against active β-catenin. Real-time quantitative PCR
demonstrated that Prickle1 expression was inversely cor-
related to active β-catenin/Axin2 levels in neuroblastoma
cells (Fig. 1c, d). Neither Vangl2 protein nor mRNA dis-
played any correlation to active β-catenin (Fig. 1c, d).
Expression of PCP core genes correlates with
neuroblastoma survival
To functionally analyze the impact of the expression level
of PCP core genes in neuroblastoma, we transiently trans-
fected SK-N-AS, SH-EP1, SK-N-BE (2) and SK-N-DZ
neuroblastoma cells with siRNA or cDNA expression con-
structs for Prickle1 or Vangl2. Knockdown of Prickle1 or
Vangl2 by siRNA resulted in an increase of neuroblastoma
cell growth in SK-N-AS cells (Prickle1, 138 % and Vangl2,
131 %) and SH-EP1 (Prickle1 119 % and Vangl2 188 %)
compared to control cells treated with a scrambled siRNA
sequence, while no changes were detected in the MYCN
amplified neuroblastoma cell lines, SK-N-BE (2) and SK-
N-DZ (Fig. 2a). To minimize the risk for eventually off-
target effects caused by the pooled siRNA’s, we repeated
the experiments using alternative siRNA’s targeting
Prickle1 and Vangl2. Similar results on cell viability were
obtained for knockdown of Prickle1 or Vangl2 in SK-N-
AS and SK-N-BE (2) cells (Additional file 1: Figure S1).
Overexpression of Prickle1 or Vangl2 significantly inhib-
ited neuroblastoma cell growth compared to cDNA con-
trol transfected cells in SK-N-AS (Prickle1 26 % and
Vangl2 44 %), SH-EP1 (Prickle1 38 % and Vangl2 60 %),
SK-N-BE (2) (Prickle1 53 % and Vangl2 58 %) and SK-N-
DZ (Prickle1 83 % and Vangl2 94 %) (Fig. 2b).
Knockdown and overexpression were confirmed with
real-time quantitative PCR in SK-N-AS and SK-N-BE
(2). All siRNA/cDNA transfection induced significant
decrease or increase of its target gene except from
siRNA against Vangl2 in SK-N-AS cells (Fig. 2c, d). The
mRNA expression of Prickle1 was not affected after
(See figure on previous page.)
Fig. 2 Knockdown and overexpression of Prickle1 and Vangl2 alter neuroblastoma cell viability and affect β-catenin expression. a Transfection with
siRNA against Prickle1 and Vangl2 resulted in a significant increase of cell viability compared to control cells transfected with scrambled siRNA
sequence (48 h) in SK-N-AS and SH-EP1, while no effects were observed in SK-N-BE (2) and SK-N-DZ cells (one-way ANOVA with Bonferroni post-test,
SK-N-AS: P < 0.0001 control vs Prickle1 P < 0.0001, control vs Vangl2 P = 0.0003; SH-EP1: P = 0.0023 control vs Vangl2 P = 0.0016). b Overexpression of
Prickle1 and Vangl2 in SK-N-AS, SH-EP1, SK-N-BE (2) and SK-N-DZ decreased cell viability significantly, compared control transfected cells (one-way
ANOVA with Bonferroni post-test, SK-N-AS: P < 0.0001 control vs Prickle1 P < 0.0001, control vs Vangl2 P = 0.0003, SH-EP1: P = 0.0004 control vs Prickle1
P = 0.0002, control vs Vangl2 P = 0.013, SK-N-BE (2): P = 0.0014 control vs Prickle1 P = 0.019 control vs Vangl2 P = 0.0025 and SK-N-DZ: P = 0.020, control
vs Prickle1 P = 0.014). Cell viability was assessed by manually courting in microscope chamber. Mean with SD are displayed, the experiments were
repeated with similar results. c, d mRNA expression of Prickle1 and Vangl2 after knockdown and overexpression of Prickle1 or Vangl2 in neuroblastoma
cells. All transfections induced significant up-/downregulation of its target gene except from siRNA Vangl2 in SK-N-AS (one-way ANOVA with Bonferroni
post-test: SK-N-AS: control vs siRNA Prickle1 P = 0.0024, control vs cDNA Prickle1 P < 0.0001 and control vs cDNA Vangl2 P < 0.0001, SK-N-BE (2): control
vs siRNA Prickle1 P < 0.0001, control vs siRNA Vangl2 P = 0.0002, control vs cDNA Prickle1 P < 0.0001 and control vs cDNA Vangl2 P = 0.0003). Data
displayed is the mean ± S.D. of three determinations, assessed by quantitative real-time PCR. e The transcriptional activity of β-catenin measured as
TOPflash luciferase activity was significantly induced after Prickle1 or Vangl2 knockdown (one-way ANOVA with Bonferroni post-test, SK-N-AS P = 0.0194,
control vs siRNA Prickle1 P = 0.034, control vs siRNA Vangl2 P = 0.021 and SK-N-BE (2) P = 0.0003, control vs siRNA Prickle1 P = 0.0002, control vs siRNA
Vangl2 P = 0.0009). Values are mean ± S.D., the experiment was repeated twice. f Protein expression of active β-catenin after upregulated or downregulated
Prickle1 or Vangl2 in SK-N-AS (48 h transfection), determined by western blotting. *P < 0.05, **P < 0.01, ***P < 0.001





Fig. 3 (See legend on next page.)
Dyberg et al. BMC Cancer  (2016) 16:259 Page 7 of 14
knockdown or overexpression of Vangl2 and similarly,
the mRNA expression of Vangl2 was not affected after
knockdown or overexpression of Prickle1 in SK-N-AS or
SK-N-BE (2) cells (Fig. 2c, d).
Altered expression of Prickle1 or Vangl2 affects active β-
catenin activity in neuroblastoma cells
To investigate if Prickle1 and Vangl2 affected canonical
Wnt signaling we studied the β-catenin transcriptional
activity after repressed expression of Prickle1 and
Vangl2 in SK-N-AS and SK-N-BE (2) cells. Knockdown
of Prickle1 or Vangl2 induced a significant increase in
TOPFlash luciferase reporter activity i.e. β-catenin tran-
scriptional activity, compared to siRNA control trans-
fected neuroblastoma cells (Fig. 2e). This increase in
active β-catenin was confirmed with western blot in
SK-N-AS cells (Fig. 2f ). Furthermore, the protein ex-
pression of active β-catenin was correspondently de-
creased in cDNA transfected SK-N-AS cells compared
to cDNA control cells (Fig. 2f ).
Alterations in the PCP signaling pathway have influence
on the activity of active β-catenin in neuroblastoma cells
To investigate if inhibition of downstream non-
canonical Wnt/PCP signaling could influence Prickle1
and Vangl2 expression, we used the ROCK inhibitors
HA1077 and Y27632. Treatment of SK-N-AS, SK-N-
BE (2) or SH-SY5Y with HA1077 resulted in in-
creased mRNA expression of Prickle1, but there was
no consistent impact on mRNA expression of Vangl2
(Fig. 3a). Similar results were obtained in SK-N-AS
and SK-N-BE (2) using Y27632 (Fig. 3b). HA1077
50 μM significantly affected the cell viability in SK-N-
AS (cell number 36 % of untreated control) and SH-
SY5Y (44 % of untreated control). In SK-N-BE (2)
both tested concentrations of HA1077 decreased the
cell viability (25 μM: 65 % and 50 μM: 27 % of un-
treated control). Y27632 80 μM induced no effects on
cell viability in any of the tested cell lines. Further,
treatment with HA1077 showed a concentration
dependent decrease in TOPFlash reporter activity i.e.
β-catenin transcriptional activity, compared to un-
treated neuroblastoma cells (Fig. 3c). The inhibitory
effect of HA1077 on β-catenin expression was further
verified in SK-N-AS cells by western blotting (Fig. 3d).
To investigate possible feedback effects between β-
catenin and Prickle1 and Vangl2, we studied the
effects on Prickle1 and Vangl2 after β-catenin knock-
down in SK-N-AS and SK-N-BE (2) cells. No signifi-
cant effects were observed on the mRNA expression
levels (Fig. 3e).
Vangl2 alterations affect cell growth, differentiation and
active β-catenin expression in neural stem cells in vitro
To study the role of Prickle1 and Vangl2 in non-
tumorigenic embryonic cells we used MYC immortalized
neural stem cells, C17.2 [13, 14]. We performed transi-
ently transfections with siRNA or cDNA expression con-
structs for Prickle1 or Vangl2 to study the impact of cell
growth. Only knockdown of Vangl2 resulted in a signifi-
cant change in cell viability. In contrast to neuroblastoma
cells, siRNA against Vangl2 decreased the cell number in
C17.2 compared to siRNA control (75 %; Fig. 4a). The
mRNA expression of Prickle1 was significantly increased
after overexpression of Prickle1, but no effect was re-
corded after siRNA Prickle1 transfection (Fig. 4b). The
mRNA expression of Vangl2 could not be quantified in
C17.2 as the levels were under the detection limit. To
study possible feedback effects between β-catenin and
Prickle1 and Vangl2 in non-tumorigenic cells, β-catenin
knockdown in C17.2 cells was performed. No significant
effects were observed on cell viability but the mRNA ex-
pression level of Prickle1 was significantly reduced in β-
catenin siRNA transfected cells compared to siRNA con-
trol transfected cells (Fig. 4a, b). Moreover, overexpression
of Vangl2 in C17.2 cells increased the amount of active β-
catenin and reduced the levels of the differentiation
marker Tuj1 (Fig. 4c, d, e). Correspondingly, Vangl2
knockdown induced neural outgrowth consistent with dif-
ferentiation and a significant decrease in β-catenin-
dependent transcriptional activity (Fig. 4f, g).
(See figure on previous page.)
Fig. 3 Inhibition of Wnt/PCP downstream effector ROCK increases Prickle1 expression and represses active β-catenin. a, b mRNA expression of
Prickle1 and Vangl2 after treatment with ROCK inhibitor HA1077 or Y27632 for 72 h; results showed a consistent increase in Prickle1 expression
(one-way ANOVA with Bonferroni post-test, SK-N-AS Prickle1: P = 0.0017, control vs HA1077 50 μM P = 0.0023, control vs HA1077 50 μM P = 0.0021,
Vangl2: P = 0.0061, control vs HA1077 50 μM P = 0.017 and SH-SY5Y Prickle1 P = 0.019, control vs HA1077 50 μM P = 0.035, control vs HA1077 50 μM
P = 0.020 and t-test, SK-N-BE (2) Vangl2 control vs Y27632 80 μM P = 0.0015). Expression of mRNA (relative to the vehicle treated control normalized to
the mean expression of the housekeeping genes) was determined by real-time RT-PCR, means with S.D. of triplicates are displayed. c Transcriptional
activity of β-catenin after HA1077 exposure; cells were transfected with a TCF/LEF luciferase reporter construct and treated with HA1077 (25 or 50 μM).
TOPFlash-dependent activity was significantly reduced as compared with the control (one-way ANOVA with Bonferroni post-test: SK-N-AS P = 0.0144,
control vs HA1077 50 μM P = 0.029 and SK-N-BE (2) P = 0.0023, control vs HA1077 50 μM P = 0.012, control vs HA1077 50 μM P = 0.0017). Data represent
the mean and SD of three determinations and the experiment was repeated twice. d Protein expression of active β-catenin following HA1077
exposure (96 h, HA1077 25 or 50 μM), determined by western blotting. e mRNA expression of Prickle1 and Vangl2 after knockdown of β-catenin in
neuroblastoma cells SK-N-AS and SK-N-BE(2), no significant changes were observed. *P < 0.05, **P < 0.01







Fig. 4 (See legend on next page.)
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Vangl2 overexpression impairs differentiation in non-
tumorigenic cells during embryonic development in vivo
To further investigate the role of Vangl2 in normal em-
bryonic development we studied the effects of alteration
in Vangl2 in mice embryos in vivo. Transgenic overex-
pression of nestin-Vangl2 in mice embryos resulted in a
drastic reduction of Tuj1+ neurons compared to wild
type embryos E9.5. However, neuronal proliferation,
assessed with cell cycle M-phase marker phosphorylated
histone H3, was unaffected in transgenic mouse embryos
compared to E9.5 wild type embryos (Fig. 5).
High expression of Prickle1 and Vangl2 correlates with
survival in neuroblastoma
To investigate the clinical importance of PCP signaling in
neuroblastoma we analyzed publicly available and validated
cohorts of gene expression signatures. High expression of
Prickle1 and Vangl2 corresponded to better survival and
(See figure on previous page.)
Fig. 4 Vangl2 alterations affect cell growth, differentiation and active β-catenin expression in neural stem cells in vitro. a siRNA against Vangl2
induced a significant decrease of cell viability compared to control cells transfected with a control siRNA sequence in C17.2 cells (one-way ANOVA
with Bonferroni post-test, control vs siRNA Vangl2 P = 0.0004). siRNA against Prickle1, siRNA against β-catenin, cDNA for Prickle1 or cDNA for Vangl2 caused
no change in cell viability. b The mRNA expression of Prickle1 after siRNA or cDNA transfection of Prickle1, Vangl2 or β-catenin. Only cDNA Prickle1 and siRNA
β-catenin induced significant changes in Prickle1 mRNA expression (one-way ANOVA with Bonferroni post-test, control vs cDNA Prickle1 P < 0.0001, control
vs siRNA β-catenin P = 0.0043). The mRNA expression of Vangl2 was below the detection limit. Expression was determined with quantitative real-time PCR,
mean with S.D. of three determinations are displayed. c-e Vangl2 overexpression reduced the frequency of Tuj1 positive C17.2 cells (C, compare i and iii).
For quantification 68 control and 84 Vangl2 cells were scored between 1 (no Tuj1 labeling) and 5 (very high labeling). All control transfected cells were
Tuj1 positive (score 2–5). Contrary, more than half (56 %) of the Vangl2 transfected cells did not display any Tuj1 label (score 1) d. Vangl2 increased active
β-catenin in the nucleus of C17.2 cells (C, compare v and vii). Active β-catenin was found in the nuclei of 33 % of the enhanced green fluorescent protein
and 48 % of the HA-Vangl2 (t-test, P = 0.0037) e, mean with S.D. are shown. Scale bar: 10 μM. f Vangl2 knockdown in C17.2 cells induced neural outgrowth,
morphology consistent with increased differentiation compared to control transfected cells. Scale bar: 10 μM. g The transcriptional activity of β-catenin
measured as TOPflash luciferase activity was significantly reduced after Vangl2 knockdown in C17.2 cells (t-test, P = 0.0092). **P < 0.01, ***P < 0.001
Fig. 5 Vangl2 overexpression impairs differentiation during embryonic development. a-f Micrographs of 10 μm transversal tissue sections of
neural mouse embryo E9.5 tissue labeled with antibodies against beta-tubulin-III (Tuj1, green) and phospho-Histone-3 (P-H3, red) and visualized
with fluorescent conjugated secondary antibodies respectively. Wild-type E9.5 mouse embryos showed an even distribution of Tuj1+ neurons in
the hindbrain part of the neuroepithelium (arrow in a), but were almost completely absent in the neuroepithelium of nestin-Vangl2 embryos (b)
and (c). The labeling against M-phase marker PH3 was similar in the neuroepithelium of both wild type and transgenic sections (arrow in (d) and
arrowhead in (e) and (f). Transgenic E9.5 Vangl2 embryos displayed impaired cranial neurulation (indicated with *[17];). Scale bars are 200 μm
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Fig. 6 (See legend on next page.)
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low-risk disease across different neuroblastoma expression
array datasets (Fig. 6a, b, Additional file 1: Figure S2).
Discussion
Neuroblastoma is a malignant neoplasm of the sympa-
thetic nervous system that affects young children.
Neuroblastoma originates from neural crest cells under-
going specification and differentiation. About 40 % of
high-risk neuroblastoma contain gene amplification of
the transcription factor MYCN often leading to high
Mycn expression whereas about 6 % of neuroblastomas
contain mutation of ALK, the majority seen in connec-
tion to MYCN gene amplification [2]. Also, other muta-
tions like PHOX2B and ATRX as well as epigenetic
aberrations have been reported in neuroblastoma [2].
However, although genetically unstable, the majority of
neuroblastomas contain no such aberrations suggesting
additional mechanisms for tumorigenesis. Also, the bio-
logical and clinical heterogeneity seen in neuroblastoma
subtypes suggest the notion of neuroblastoma being a
spectrum of diseases.
We show that core proteins within the non-canonical
Wnt/PCP signaling cascade are differentially expressed
in neuroblastoma and that the expression levels of these
proteins affect neuroblastoma survival. Overexpression
of Prickle1 or Vangl2 was coupled to decreased neuro-
blastoma growth and reduced expression of active β-
catenin (summarized in Fig. 6c). This was also evident
from analysis of expression arrays of primary neuroblast-
oma where high expression of Prickle1 and Vangl2
mRNA are significantly coupled to low-risk disease and
good patient survival. Inhibiting the activity of ROCK1/
2, important mediators of Rac/Rho signaling coupled to
PCP activity also resulted in increased expression of
Prickle1 and inhibition of β-catenin activity. We used
HA1077 and Y-27632 to inhibit the activity of ROCK in
neuroblastoma cells. HA1077 was more effective in
stimulating Prickle1 expression, inhibiting β-catenin ac-
tivity and suppressing neuroblastoma growth as com-
pared to Y-27632. This despite that both compounds
binds to the ATP binding pocket of ROCKs with similar
affinity (Ki 330 nM for HA1077 and 220–300 nM for Y-
27632) leading to effective inhibition of the kinase activ-
ity [20]. Although off-target effects have been described
for both compounds [21], we currently do not have any
good explanation for these differences in the activity. In
contrast to neuroblastoma cells, both non-tumorigenic
neural cells and transgenic mouse embryos with overex-
pression of Vangl2 in nestin-expressing cells showed in-
creased active β-catenin and reduced differentiation.
These results indicate that expression of PCP core proteins
have different modes of action in neuroblastoma com-
pared to non-tumorigenic neural cells and emphasize the
complexity of the cell polarity network in different tissues.
PCP signaling is fundamental for proper migration, polar-
ity, locomotion and EMT of cells during embryonal devel-
opment. Vangl2 is described to play an important role in
developing CNS and mutations in Vangl2 are coupled to
neural tube defects in mice and humans [22, 23]. Cell mi-
gration, polarity and EMT are processes also important
during initiation, invasion and metastasis of tumor cells.
Deregulated expression of molecules within the PCP
signaling cascade has been shown in cancers of different
origin including mammary gland tumors, hepatocellular
carcinoma, colorectal, lung and prostate cancer and
leukemia [10, 24–27]. However, contradictive reports indi-
cate key molecules within the PCP signaling pathway as
both tumor promoters and suppressors [10, 28]. For in-
stance, Vangl1 has been shown to both inhibit colorectal
carcinoma metastasis in mice but also to promote and in-
duce colorectal cancer metastasis in the same mouse
model [29, 30]. Expression of the PCP core protein
Prickle1 is downregulated in hepatocellular carcinoma
whereas both Prickle1 and Vangl1 expression inhibit hepa-
tocellular carcinoma growth in vitro [31, 32]. It is also
demonstrated in hepatocellular carcinoma that high ex-
pression of Prickle1 inhibits active β-catenin though pro-
moting ubiquitination and degradation of Dishevelled [31].
The observation in our study, that high expression of the
PCP proteins Prickle1 or Vangl2 reduces the growth of
neuroblastoma cells, further supports the notion that key
proteins within the PCP signaling pathway may act as
tumor suppressors. Similar to what we show for Prickle1, it
has been reported that Scribble, another PCP protein, may
inhibit β-catenin signaling and act as a tumor suppressor in
mammary gland, prostate and lung cancer [10]. Taken
together, accumulating evidence suggest that PCP proteins
are important regulators of several cancer hallmarks and
have potential both as diagnostic biomarkers for cancer
aggressiveness and as future therapeutic targets.
Conclusions
High expression of the PCP core proteins Prickle1 and
Vangl2 reduce the growth of neuroblastoma cells and
(See figure on previous page.)
Fig. 6 High expression of Prickle1 and Vangl2 correlates to survival and low-stage disease in neuroblastoma. a Kaplan-Meier survival estimates of high
vs low expression of Prickle1 and Vangl2 in neuroblastoma expression cohorts analyzed using the microarray analysis and visualization platform (http://
r2.amc.nl). b Box-plot of Prickle1 and Vangl2 expression correlated to neuroblastoma high-risk vs low/intermediate-risk disease stage. P-values were
corrected for multiple testing (One-way Anova with Bonferroni post-test). c Schematic image over the possible interactions between Prickle1/Vangl2
and β-catenin in neuroblastoma
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correspond to low-stage disease and patient survival.
Our data also suggest that Prickle1 and Vangl2 expression
have different modes of action in tumorigenic cells
compared to normal cells. Our results suggest that the
activity of the non-canonical Wnt/PCP signaling pathway
is important for neuroblastoma development and that
PCP proteins have potential both as diagnostic markers
for neuroblastoma and as therapeutic targets.
Additional file
Additional file 1: Knockdown of Prickle1 or Vangl2 alters neuroblastoma cell
viability. Transfection of neuroblastoma cells using alternative siRNA’s against
Prickle1 and Vangl2 resulted in a significant increase of cell viability compared
to control cells transfected with scrambled siRNA sequence (48 h) in SK-N-AS.
Also in SK-N-BE (2) an increase were recorded after siRNA against Prickle1
(one-way ANOVA with Bonferroni post-test, SK-N-AS: P < 0.0001 control vs
Prickle1 P < 0.0001, control vs Vangl2 P < 0.0001; SK-N-BE (2): P = 0.026:
control vs Prickle1 P = 0.017). Figure S2: Correlation between expression of
Prickle1 and Vangl2 and survival in neuroblastoma. a) Kaplan-Meier survival
estimates of high vs low expression of Prickle1 and Vangl2 in neuroblastoma
expression cohorts analyzed using the microarray analysis and visualization
platform (http://r2.amc.nl). b Box-plot of Prickle1 and Vangl2 expression
correlated to neuroblastoma disease stage (PPTX 486 kb)
Abbreviations
DMEM: dulbecco’s modified eagle’s medium; E: embryonic day;
EMT: epithelial-mesenchymal transition; fb: forebrain; FBS: fetal bovine serum;
hb: hindbrain; mb: midbrain; PBS: phosphate-buffered saline; PCP: planar cell
polarity; ROCK: rho-associated coiled-coil kinase; siRNA: silencing RNA;
TCF/LEF: T-cell factor/lymphoid enhancing factor; Vangl2: van Gogh-like 2;
Wnt: wingless; WT: wild-type.
Competing interests
The authors declare no conflict of interest.
Authors’ contributions
CD and PP initiated the study, participated in its design, carried out the in
vitro studies, and wrote the manuscript. CD also performed the gene
signature analysis. BHH and MW carried out the PCR analysis. HL and PK
participated in the design and coordination of the study. TR initiated the
study, contributed to the experimental design and analysis and performed
the in vivo studies. JIJ and MW participated in the design of the study,
contributed to the data analysis and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We wish to thank Dr. Alexander Bassuk and Dr. Lelita Braiterman for
expression constructs. This work was supported by grants from The Swedish
Childhood Cancer Foundation, The Swedish Cancer Society, The Swedish
Foundation for Strategic Research (www.nnbcr.se), Swedish Research Council,
The Mary Béve Foundation, Märta and Gunnar V Philipson Foundation,
Anna-Brita and Bo Castegren Memorial Foundation, and Sigurd and Elsa
Goljes Memorial Foundation. PP was supported by a FoUU grant from
TioHundra AB.
Author details
1Childhood Cancer Research Unit, Department of Women’s and Children’s
Health, Karolinska Institutet, Astrid Lindgren Children’s Hospital Q6:05, SE-171
76 Stockholm, Sweden. 2Neonatal Research Unit, Department of Women’s
and Children’s Health, Astrid Lindgren Children’s hospital, Q2:07, Karolinska
Institutet, SE-171 76 Stockholm, Sweden. 3Academic Primary Health Care
Center, TioHundra AB, Box 905 SE-761 29 Norrtälje, Sweden. 4Department of
Pediatrics, University-Hospital of Northern-Norway (UNN), 9037 Tromsø,
Norway.
Received: 9 April 2015 Accepted: 23 March 2016
References
1. Johnsen J, Kogner P, Albihn A, Henriksson M. Embryonal neural tumours
and cell death. Apoptosis. 2009;14(4):424–38.
2. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy.
Annu Rev Med. 2015;66:49–63.
3. Maguire LH, Thomas AR, Goldstein AM. Tumors of the neural crest:
Common themes in development and cancer. Dev Dyn. 2014.
4. Takahashi Y, Sipp D, Enomoto H. Tissue interactions in neural crest cell
development and disease. Science. 2013;341(6148):860–3.
5. Sauka-Spengler T, Bronner-Fraser M. Evolution of the neural crest viewed
from a gene regulatory perspective. Genesis. 2008;46(11):673–82.
6. Mayor R, Theveneau E. The role of the non-canonical Wnt-planar cell
polarity pathway in neural crest migration. Biochem J. 2014;457(1):19–26.
7. Etchevers HC, Amiel J, Lyonnet S. Molecular bases of human
neurocristopathies. Adv Exp Med Biol. 2006;589:213–34.
8. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):
2202–11.
9. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A,
Maris JM, Hogarty MD. Deregulated Wnt/beta-catenin program in high-risk
neuroblastomas without MYCN amplification. Oncogene. 2008;27(10):1478–88.
10. Godde NJ, Pearson HB, Smith LK, Humbert PO. Dissecting the role of
polarity regulators in cancer through the use of mouse models. Exp Cell
Res. 2014;328(2):249–57.
11. Hatakeyama J, Wald JH, Printsev I, Ho HY, Carraway 3rd KL. Vangl1 and
Vangl2: planar cell polarity components with a developing role in cancer.
Endocr Relat Cancer. 2014;21(5):R345–56.
12. Kryh H, Caren H, Erichsen J, Sjoberg RM, Abrahamsson J, Kogner P, Martinsson
T. Comprehensive SNP array study of frequently used neuroblastoma cell lines;
copy neutral loss of heterozygosity is common in the cell lines but
uncommon in primary tumors. BMC Genomics. 2011;12:443.
13. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwieg EA, Cepko CL.
Multipotent neural cell lines can engraft and participate in development of
mouse cerebellum. Cell. 1992;68(1):33–51.
14. Jaderstad J, Jaderstad LM, Li J, Chintawar S, Salto C, Pandolfo M, Ourednik V,
Teng YD, Sidman RL, Arenas E, et al. Communication via gap junctions
underlies early functional and beneficial interactions between grafted neural
stem cells and the host. Proc Natl Acad Sci U S A. 2010;107(11):5184–9.
15. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of
image analysis. Nat Methods. 2012;9(7):671–5.
16. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E.
Consortium: an integrated molecular analysis of genomes and their
expression. Genomics. 1996;33(1):151–2.
17. Lindqvist M, Horn Z, Bryja V, Schulte G, Papachristou P, Ajima R, Dyberg C,
Arenas E, Yamaguchi TP, Lagercrantz H, et al. Vang-like protein 2 and Rac1
interact to regulate adherens junctions. J Cell Sci. 2010;123(Pt 3):472–83.
18. Lothian C, Lendahl U. An evolutionarily conserved region in the second
intron of the human nestin gene directs gene expression to CNS progenitor
cells and to early neural crest cells. Eur J Neurosci. 1997;9(3):452–62.
19. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal
research. PLoS Biol. 2010;8(6), e1000412.
20. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho GTPase
pathway as viable drug target. Curr Med Chem. 2009;16(11):1355–65.
21. Breitenlechner C, Gassel M, Hidaka H, Kinzel V, Huber R, Engh RA, Bossemeyer
D. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and
H-1152P: structural basis of selectivity. Structure. 2003;11(12):1595–607.
22. Kibar Z, Salem S, Bosoi CM, Pauwels E, De Marco P, Merello E, Bassuk AG,
Capra V, Gros P. Contribution of VANGL2 mutations to isolated neural tube
defects. Clin Genet. 2011;80(1):76–82.
23. Kibar Z, Vogan KJ, Groulx N, Justice MJ, Underhill DA, Gros P. Ltap, a
mammalian homolog of Drosophila Strabismus/Van Gogh, is altered in the
mouse neural tube mutant Loop-tail. Nat Genet. 2001;28(3):251–5.
24. Hawkins ED, Russell SM. Upsides and downsides to polarity and asymmetric
cell division in leukemia. Oncogene. 2008;27(55):7003–17.
25. Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D,
Elsum I, Greenfield A, Tuveson DA, Simon R, et al. SCRIB expression is
deregulated in human prostate cancer, and its deficiency in mice promotes
prostate neoplasia. J Clin Investig. 2011;121(11):4257–67.
Dyberg et al. BMC Cancer  (2016) 16:259 Page 13 of 14
26. Piazzi G, Selgrad M, Garcia M, Ceccarelli C, Fini L, Bianchi P, Laghi L,
D'Angelo, Paterini P, Malfertheiner P, et al. Van-Gogh-like 2 antagonises the
canonical WNT pathway and is methylated in colorectal cancers.
Brit J Cancer. 2013;108(8):1750–6.
27. Zhan LX, Rosenberg A, Bergami KC, Yu M, Xuan ZY, Jaffe AB, Allred C,
Muthuswamy SK. Deregulation of Scribble Promotes Mammary
Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma. Cell. 2008;
135(5):865–78.
28. Wang Y. Wnt/Planar cell polarity signaling: a new paradigm for cancer
therapy. Mol Cancer Ther. 2009;8(8):2103–9.
29. Lee JH, Cho ES, Kim MY, Seo YW, Kho DH, Chung IJ, Kook H, Kim NS, Ahn
KY, Kim KK. Suppression of progression and metastasis of established colon
tumors in mice by intravenous delivery of short interfering RNA targeting
KITENIN, a metastasis-enhancing protein. Cancer Res. 2005;65(19):8993–9003.
30. Lee JH, Park SR, Chay KO, Seo YW, Kook H, Ahn KY, Kim YJ, Kim KK. KAI1
COOH-terminal interacting tetraspanin (KITENIN), a member of the
tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and
enhances metastasis of cancer. Cancer Res. 2004;64(12):4235–43.
31. Chan DW, Chan CY, Yam JW, Ching YP, Ng IO. Prickle-1 negatively regulates
Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/
degradation in liver cancer. Gastroenterology. 2006;131(4):1218–27.
32. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer?
Cell Death Differ. 2011;18(9):1470–7.
33. Wickstrom M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevag
OM, Larsson R, Kogner P, Zaphiropoulos PG, Johnsen JI. Targeting the
hedgehog signal transduction pathway at the level of GLI inhibits
neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013;132(7):
1516–24.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dyberg et al. BMC Cancer  (2016) 16:259 Page 14 of 14
